WuXi AppTec has appointed Dr. David Chang as Chief Executive Officer of WuXi Advanced Therapies business unit (WuXi ATU), WuXi AppTec’s cell and gene therapy CDMO. In this new executive role, Dr. Chang will provide strategic, scientific and operational leadership to the company’s global cell and gene therapy R&D and manufacturing services.

Dr. Chang brings strong leadership and experience in cell and gene therapy and biopharmaceutical technical development, manufacturing operations, engineering and strategy.  Prior to joining WuXi AppTec, Dr. Chang was Corporate Vice President and Head of Cell Therapy Global Manufacturing at Celgene, a Bristol Myers Squibb, where he oversaw the CAR-T manufacturing network and the global manufacturing sciences and technologies teams. He also served as the Global Head of Engineering and Strategy at Roche, Switzerland, after roles that included Vice President/Site Head of Roche Shanghai Technical Operations, China.

“We are delighted to welcome Dr. Chang as CEO of WuXi ATU to lead our cell and gene therapy CDMO business to the next stage of growth,” said Mr. Edward Hu, Vice Chairman and Global Chief Investment Officer of WuXi AppTec. “We believe that cell and gene therapies represent a tremendous opportunity for the healthcare industry to deliver more effective and innovative personalized solutions to patients. Dr. Chang’s leadership and deep expertise in this field will further advance WuXi AppTec’s long-standing support for its customers and their mission to advance discoveries and development in the life and health sciences and deliver groundbreaking treatment to those in need.”